143 related articles for article (PubMed ID: 1164466)
1. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
Currie GA; McElwain TJ
Br J Cancer; 1975 Feb; 31(2):143-56. PubMed ID: 1164466
[TBL] [Abstract][Full Text] [Related]
2. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
Hedley DW; McElwain TJ; Currie GA
Eur J Cancer (1965); 1977 Oct; 13(10):1169-73. PubMed ID: 923614
[No Abstract] [Full Text] [Related]
3. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
Hedley DW; McElwain TJ; Currie GA
Br J Cancer; 1978 Apr; 37(4):491-6. PubMed ID: 646922
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
Newlands ES; Oon CJ; Roberts JT; Elliott P; Mould RF; Topham C; Madden FJ; Newton KA; Westbury G
Br J Cancer; 1976 Aug; 34(2):174-9. PubMed ID: 962994
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
6. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
Kokoschka EM; Cerni C; Micksche M
Oncology; 1977; 34(5):229-33. PubMed ID: 917456
[TBL] [Abstract][Full Text] [Related]
7. Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
Thatcher N; Blackledge G; Palmer MK; Crowther D
Eur J Cancer (1965); 1981 Apr; 17(4):465-9. PubMed ID: 7308256
[No Abstract] [Full Text] [Related]
8. [Possibilities of immunotherapy in malignant melanoma].
Lewis MG
Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
[TBL] [Abstract][Full Text] [Related]
9. BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma.
Morton DL; Eilber FR; Holmes EC; Sparks FC; Ramming K
Med Clin North Am; 1976 May; 60(3):431-9. PubMed ID: 1271888
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
12. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
13. Immunotherapy of malignant melanoma.
Thiers BH
J Am Acad Dermatol; 1982 Apr; 6(4 Pt 1):559-62. PubMed ID: 6176602
[No Abstract] [Full Text] [Related]
14. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
Mitchell MS; Mokyr MB; Davis JM
J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant immunotherapy of malignant melanoma.
Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
[TBL] [Abstract][Full Text] [Related]
16. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
[TBL] [Abstract][Full Text] [Related]
17. Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
Veronesi U; Beretta G
Recent Results Cancer Res; 1978; 68():375-9. PubMed ID: 752873
[No Abstract] [Full Text] [Related]
18. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
19. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
20. Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy.
Schmitt E; Meuret G; Waldermann F; Hagedorn M
Arch Dermatol Res; 1979 May; 264(3):319-26. PubMed ID: 464648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
